Consensus Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/04/2026 am IST			5-day change	1st Jan Change
45.86 ^USD	+2.00%		+4.25%	+4.63%

25/03	Recursion Pharmaceuticals Announces Executive Changes, Effective April 6, 2026	CI
11/03	Exelixis, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 12:00 PM

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

a.4LJOwzLz9yf7n0SKF8-5EHTiFFnd2XIC7L5VzzYWZ_I.2IEJrF3DlkbIqiL_IqHAVSKyZ2mrtDFAtc06nllzBoWjxT6ge4OuQKn6CQ~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

02/03	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
11/02	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02/02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
09/01	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
08/01	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
05/01	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
05/01	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
06/11	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
05/11	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
04/11	Exelixis Shares Fall After Guggenheim Downgrade	MT
03/11	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
22/25/22	Exelixis Shares Rise After Leerink Partners Upgrade	MT
21/25/21	Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38	MT
18/25/18	Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	CI
30/25/30	UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating	MT
29/25/29	Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial...
29/25/29	RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating	MT
29/25/29	Truist Cuts Price Target on Exelixis to $49 From $56, Keeps Buy Rating	MT
29/25/29	Morgan Stanley Lowers Price Target on Exelixis to $46 From $48, Keeps Overweight Rating	MT
15/25/15	Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating	MT
08/25/08	RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45	MT
07/25/07	RBC Raises Price Target on Exelixis to $45 From $40, Keeps Outperform Rating	MT
24/25/24	Stephens Upgrades Exelixis to Overweight From Equalweight, Adjusts Price Target to $60 From $29	MT
23/25/23	Truist Adjusts Price Target on Exelixis to $55 From $43, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					+2.12%
	ARGENX SE					+19.32%
	WUXI APPTEC CO., LTD.					+26.35%
	INSMED INCORPORATED					+38.43%
	BIONTECH SE					+34.2%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.81%
	GENMAB A/S					+21.18%
	AKESO, INC.					+26.3%
	SUMMIT THERAPEUTICS INC.					+45.52%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.9%
	Average					+24.71%
	Weighted average by Cap.					+25.84%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

45.86USD

Average target price

46.83USD

Spread / Average Target

+2.12%

High Price Target

60.00USD

Spread / Highest target

+30.83%

Low Price Target

35.00USD

Spread / Lowest Target

-23.68%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Morgan Stanley
Truist Securities
BofA Securities
UBS
Guggenheim
Leerink Partners
Stephens Inc.
Wells Fargo Securities
Oppenheimer
William O'Neil & Co
BMO Capital
Barclays
BTIG
Citigroup
JMP Securities
SVB Securities LLC
Credit Suisse
EF Hutton
Piper Sandler
Jefferies & Co.
HC Wainwright
Needham & Co.
Goldman Sachs
Wolfe Research